All stock lists
Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
Healthcare · Biotechnology
10.41-0.43 (-4.01%)
Insider Score
––Not scored
GLUE Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
GLUE Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 8.97 M | 4.21 M | 2.78 M | 12.77 M | 23.19 M | 84.93 M |
| Revenue Growth (YoY) | -61.33 % | -95.04 % | -95.41 % | 38.54 % | 394.01 % | 7882.05 % |
| Cost of Revenue | 0.00 | 2.03 M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.97 M | 2.18 M | 2.78 M | 12.77 M | 23.19 M | 84.93 M |
| SG&A Expense | 10.13 M | 10.18 M | 10.52 M | 9.06 M | 8.10 M | 8.70 M |
| R&D Expense | 47.96 M | 44.07 M | 41.98 M | 36.68 M | 30.65 M | 32.19 M |
| Operating Expenses | 58.10 M | 52.22 M | 52.50 M | 45.74 M | 38.75 M | 40.89 M |
| Operating Income | -49.13 M | -50.03 M | -49.72 M | -32.98 M | -15.55 M | 44.04 M |
| Pretax Income | -43.19 M | -44.45 M | -46.08 M | -30.26 M | -11.10 M | 47.71 M |
| Tax Provision | 208.00 K | 52.00 K | 59.00 K | -3.18 M | 1.20 M | 822.00 K |
| Net Income | -43.40 M | -44.50 M | -46.13 M | -27.08 M | -12.29 M | 46.88 M |
| EPS (Basic) | -0.51 | -0.53 | -0.70 | -0.44 | -0.20 | 0.57 |
| EPS (Diluted) | -0.51 | -0.53 | -0.70 | -0.44 | -0.20 | 0.57 |
| Shares Outstanding | 85.23 M | 84.32 M | 65.54 M | 61.79 M | 61.72 M | 82.15 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.